

Peter Albers

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3232422/peter-albers-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

296
papers

9,379
citations

51
h-index

88
g-index

355
ext. papers

11,416
ext. citations

4.6
avg, IF

5.8
L-index

#	Paper	IF	Citations
296	Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights.. <i>Clinical Epigenetics</i> , 2022 , 14, 5	7.7	1
295	Can magnetic resonance imaging replace conventional computerized tomography for follow-up of patients with testicular cancer? A systematic review.. <i>World Journal of Urology</i> , 2022 , 1	4	0
294	Age-stratified outcomes after radical prostatectomy in a randomized setting (LAP-01): do younger patients have more to lose?. <i>World Journal of Urology</i> , 2022 , 40, 1151	4	0
293	Cognitive function in patients undergoing cystectomy for bladder cancer - results from a prospective observational study.. <i>Therapeutic Advances in Urology</i> , 2022 , 14, 17562872221087660	3.2	1
292	First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment : A comprehensive review compiled by the German Testicular Cancer Study Group.. <i>World Journal of Urology</i> , 2022 , 1	4	0
291	The PRIMETEST trial: Prospective phase II trial of primary retroperitoneal lymph node dissection (RPLND) in stage II A/B patients with seminoma.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 420-420	2.2	0
290	Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility.. <i>World Journal of Urology</i> , 2022 , 1	4	0
289	How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence.. <i>World Journal of Urology</i> , 2022 , 1	4	0
288	Short-term and long-term outcomes after resection of thoracic growing teratoma syndrome. <i>World Journal of Urology</i> , 2021 , 39, 2579-2585	4	1
287	Preoperative clinical and radiographic predictors of major vascular surgery in patients with testicular cancer undergoing post-chemotherapy residual tumor resection (PC-RPLND). <i>World Journal of Urology</i> , 2021 , 1	4	1
286	Postchemotherapy Residual Tumor Resection in Patients with Elevated Tumor Markers. <i>Journal of Urology</i> , 2021 , 101097JU00000000000002270	2.5	
285	Clinical dilemmas in local and regional testis cancer. <i>Canadian Urological Association Journal</i> , 2021 , 15, E58-E64	1.2	1
284	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 525-537	21.7	73
283	Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01). <i>European Urology</i> , 2021 , 79, 750-759	10.2	22
282	ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. <i>Nature</i> , 2021 , 595, 432-437	50.4	59
281	Reply to Laura Evangelista and Egesta Lopci's Letter to the Editor re: Hendrik Van Poppel, René Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. <i>Eur Urol</i> 2021 ;79:327-9:	10.2	
280	Early Detection of Prostate Cancer in High-risk Patients with Negative Fusion Biopsy. <i>European Urology</i> , 2021 , 79, 327-333 Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial. <i>World Journal of Urology</i> , 2021 , 39, 65-74		2

279	Molecular and epigenetic pathogenesis of germ cell tumors. <i>Asian Journal of Urology</i> , 2021 , 8, 144-154	2.7	5
278	Surgical treatment of metastatic germ cell cancer. <i>Asian Journal of Urology</i> , 2021 , 8, 155-160	2.7	1
277	Re: The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis. <i>European Urology</i> , 2021 , 79, 160-161	10.2	
276	Aktuelle Entwicklungen und Behandlungsmöglichkeiten für das Growing-Teratoma-Syndrom. <i>Onkologe</i> , 2021 , 27, 21-28	0.1	
275	Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages. <i>Urologia Internationalis</i> , 2021 , 105, 169-180	1.9	16
274	Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II - Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Fertility, and Quality of Life. <i>Urologia Internationalis</i> , 2021 , 105, 181-191	1.9	8
273	The pioneer and differentiation factor FOXA2 is a key driver of yolk-sac tumour formation and a new biomarker for paediatric and adult yolk-sac tumours. <i>Journal of Cellular and Molecular Medicine</i> , 2021 , 25, 1394-1405	5.6	3
272	Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 1273-1274	4.9	
271	Solving problems is smart, preventing them is wise: Lessons learned from the 2nd International DKFZ Conference on Cancer Prevention. <i>International Journal of Cancer</i> , 2021 , 148, 3086-3096	7.5	0
270	A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer. <i>European Urology Oncology</i> , 2021 , 4, 731-739	6.7	10
269	The signal transducer CD24 suppresses the germ cell program and promotes an ectodermal rather than mesodermal cell fate in embryonal carcinomas. <i>Molecular Oncology</i> , 2021 ,	7.9	1
268	Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohort. <i>European Journal of Cancer</i> , 2021 , 155, 61-70	7.5	5
267	Late relapsing germ cell tumors with elevated tumor markers. <i>World Journal of Urology</i> , 2021 , 1	4	0
266	The developmental origin of cancers defines basic principles of cisplatin resistance. <i>Cancer Letters</i> , 2021 , 519, 199-210	9.9	2
265	Comparison and prediction of artefact severity due to total hip replacement in 1.5 T versus 3 T MRI of the prostate. <i>European Journal of Radiology</i> , 2021 , 144, 109949	4.7	1
264	On the Geometric Mechanics of Assignment Flows for Metric Data Labeling. <i>Lecture Notes in Computer Science</i> , 2021 , 398-410	0.9	1
263	CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms. <i>British Journal of Cancer</i> , 2020 , 123, 378-391	8.7	16
262	A Canadian approach to the regionalization of testis cancer: A review. <i>Canadian Urological Association Journal</i> , 2020 , 14, 346-351	1.2	

261	Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology. <i>Cancers</i> , 2020 , 12,	6.6	12
260	Controversies in the management of clinical stage 1 testis cancer. <i>Canadian Urological Association Journal</i> , 2020 , 14, E537-E542	1.2	0
259	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. <i>European Urology</i> , 2020 , 78, 661-669	10.2	30
258	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. <i>European Urology</i> , 2020 , 78, 779-782	10.2	6
257	IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5000-5000	2.2	33
256	Late toxicities and recurrences in patients with clinical stage I nonseminomatous germ cell tumor after one cycle of adjuvant BEP versus primary retroperitoneal lymph node dissection: A 13-years follow-up analysis of a phase III trial cohort.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5512-5512	2.2	1
255	MRT-(inbore)-Biopsie zur sicheren Detektion kleiner oder ungünstig gelegener Prostatakazinome bei negativer MRT/Ultraschall-Fusionsbiopsie. <i>Tumor Diagnostik Und Therapie</i> , 2020 , 41, 399-402	0.1	
254	Reply by Authors. <i>Journal of Urology</i> , 2020 , 204, 302	2.5	
253	Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of Ga-PSMA and C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. <i>Journal of Urology</i> , 2020 , 204, 296-302	2.5	17
252	Robotic Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer. <i>Journal of Urology</i> , 2020 , 204, 1242-1248	2.5	6
251	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. <i>World Journal of Urology</i> , 2020 , 38, 1959-1968	4	12
250	Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies. <i>Journal of Personalized Medicine</i> , 2020 , 10,	3.6	3
249	Value of Dynamic Contrast-Enhanced (DCE) MR Imaging in Peripheral Lesions in PI-RADS-4 Patients. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2020 , 192, 441-447	2.3	11
248	Regulates Transcription and the Epigenetic Landscape via POLE and DMAP1 while Deficiency or Pharmacological Inhibition Sensitizes Germ Cell Tumor Cells to ATR Inhibition. <i>Cancers</i> , 2020 , 12,	6.6	9
247	A compactness result for non-local unregularized gradient flow lines. <i>Journal of Fixed Point Theory and Applications</i> , 2019 , 21, 1	1.4	3
246	Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019 , 76, 142-150	10.2	51
245	Prospective comparison of whole-body MRI and Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 1542-1550	8.8	32
244	The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. <i>European Urology</i> , 2019 , 76, 179-186	10.2	10

243	Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. <i>European Urology</i> , 2019 , 75, 310-318	10.2	66
242	An iterated graph construction and periodic orbits of Hamiltonian delay equations. <i>Journal of Differential Equations</i> , 2019 , 266, 2466-2492	2.1	5
241	Management, Treatment, and Molecular Background of the Growing Teratoma Syndrome. <i>Urologic Clinics of North America</i> , 2019 , 46, 419-427	2.9	9
240	The PRIMETEST trial: Interim analysis of a phase II trial for primary retroperitoneal lymph node dissection (RPLND) in stage II A/B seminoma patients without adjuvant treatment.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 507-507	2.2	14
239	Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in patients with testis cancer in the salvage setting.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 524-524	2.2	2
238	Nichtseminom CS I: Adjuvante Therapie. <i>Springer Reference Medizin</i> , 2019 , 1-7	0	
237	Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse. <i>World Journal of Urology</i> , 2019 , 37, 2081-2090	4	4
236	Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. <i>European Urology</i> , 2019 , 75, 604-611	10.2	112
235	Preservation of Ejaculatory Function After Postchemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND) in Patients With Testicular Cancer: Template vs. Bilateral Resection. <i>Frontiers in Surgery</i> , 2018 , 5, 80	2.3	13
234	Non-risk-adapted Surveillance for Stage I Testicular Cancer: Critical Review and Summary. <i>European Urology</i> , 2018 , 73, 899-907	10.2	36
233	Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. <i>European Urology</i> , 2018 , 73, 394-405	10.2	41
232	Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate. <i>Journal of Urology</i> , 2018 , 199, 691-698	2.5	26
231	Current Utilization and Acceptance of Multiparametric MRI in the Diagnosis of Prostate Cancer. A Regional Survey. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2018 , 190, 419-426	2.3	6
230	Comparison of 2-Year Oncological Outcome and Early Recurrence Patterns in Patients with Urothelial Bladder Carcinoma Treated with Open or Robot-Assisted Radical Cystectomy with an Extracorporeal Urinary Diversion. <i>Urologia Internationalis</i> , 2018 , 101, 224-231	1.9	6
229	Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	15
228	Neoadjuvant Chemotherapy in Muscle Invasive Urothelial Bladder Cancer 2018 , 241-248		
227	Surgical management and outcomes of patients with bone metastases in germ cell tumors: A case series. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 82.e1-82.e5	2.8	7
226	Retroperitoneal lymph node dissection in the setting of elevated markers. <i>Current Opinion in Urology</i> , 2018 , 28, 435-439	2.8	6

225	Testicular cancer. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 29	51.1	164
224	Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy-Are 2 Biopsy Cores per Magnetic Resonance Imaging Lesion Required?. <i>Journal of Urology</i> , 2018 , 200, 1030-1034	2.5	18
223	Discordant prostate specific antigen test results despite WHO assay standardization. <i>International Journal of Biological Markers</i> , 2018 , 33, 275-282	2.8	6
222	Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy. <i>European Urology Focus</i> , 2017 , 3, 470-479	5.1	3
221	Local systems on the free loop space and finiteness of the Hofer-Zehnder capacity. <i>Mathematische Annalen</i> , 2017 , 367, 1403-1428	1	2
220	Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 544.e11-544.e23	2.8	13
219	Magnetic resonance imaging of the prostate at 1.5 versus 3.0T: A prospective comparison study of image quality. <i>European Journal of Radiology</i> , 2017 , 90, 192-197	4.7	61
218	Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3525-3528	2.2	45
217	PD53-11 PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) IN STAGE II A/B SEMINOMA PATIENTS WITHOUT ADJUVANT TREATMENT: A PHASE II TRIAL (PRIMETEST). <i>Journal of Urology</i> , 2017 , 197,	2.5	3
216	Positive loops and (L^{∞}) -contact systolic inequalities. <i>Selecta Mathematica, New Series</i> , 2017 , 23, 2491-2521	0.8	2
215	Theranostik. <i>Onkologe</i> , 2017 , 23, 597-608	0.1	
214	Targeting mTOR in urothelial cancer-Beating a dead horse or ready for prime time?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 600-601	2.8	
213	Vanishing of Rabinowitz Floer homology on negative line bundles. <i>Mathematische Zeitschrift</i> , 2017 , 285, 493-517	0.7	5
212	Residualtumorsektion nach Chemotherapie. <i>Onkologe</i> , 2017 , 23, 107-114	0.1	
211	Sinnhaftigkeit des PSA - Screenings. <i>Onkologe</i> , 2017 , 23, 429-437	0.1	
210	Re: Reevaluating PSA Testing Rates in the PLCO Trial. <i>European Urology</i> , 2017 , 71, 300	10.2	1
209	¹¹ C-acetate positron-emission tomography/computed tomography imaging for detection of recurrent disease after radical prostatectomy or radiotherapy in patients with prostate cancer. <i>BJU International</i> , 2017 , 120, 337-342	5.6	3
208	Die Rehabilitation des PSA-Werts. <i>Uro-News</i> , 2017 , 21, 40-43	0	

207	Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	8
206	Comparison of patient comfort between MR-guided in-bore and MRI/ultrasound fusion-guided prostate biopsies within a prospective randomized trial. <i>World Journal of Urology</i> , 2016 , 34, 215-20	4	20
205	Next Generation Screening beim Prostatakarzinom. <i>Uro-News</i> , 2016 , 20, 52-55	0	
204	Residualtumorresektion: Indikationen, Durchführung und Komplikationen. <i>Uro-News</i> , 2016 , 20, 29-34	0	
203	Lebensqualität bei Hodentumoren: ein Zyklus PEB versus RLA. <i>Uro-News</i> , 2016 , 20, 34-38	0	
202	PSA-basierte Prostatakarzinom-Früherkennung. <i>Onkologe</i> , 2016 , 22, 558-561	0.1	
201	Quality assessment in prostate cancer centers certified by the German Cancer Society. <i>World Journal of Urology</i> , 2016 , 34, 665-72	4	11
200	Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours. <i>European Urology</i> , 2016 , 69, 518-25	10.2	7
199	Targeted MRI-guided prostate biopsy: are two biopsy cores per MRI-lesion required?. <i>European Radiology</i> , 2016 , 26, 3858-3864	8	19
198	MRI-Guided In-Bore Biopsy: Differences Between Prostate Cancer Detection and Localization in Primary and Secondary Biopsy Settings. <i>American Journal of Roentgenology</i> , 2016 , 206, 92-9	5.4	44
197	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. <i>European Urology</i> , 2016 , 69, 634-641	10.2	47
196	Cuplength estimates in Morse cohomology. <i>Journal of Topology and Analysis</i> , 2016 , 08, 243-272	0.3	3
195	Limited versus extended pelvic lymphadenectomy in patients with bladder cancer undergoing radical cystectomy: Survival results from a prospective, randomized trial (LEA AUO AB 25/02).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4503-4503	2.2	24
194	PRINCE: A phase III study comparing intermittent docetaxel therapy versus continuous docetaxel therapy in patients with castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5005-5005 ¹	2.2	24
193	Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 386-386	2.2	
192	Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. <i>Oncolmmunology</i> , 2016 , 5, e1107698	7.2	27
191	Quality of life in patients with cisplatin-resistant urothelial cancer: Typical ailments and effect of paclitaxel-based salvage therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 256.e15-21 ⁵	2.8	5
190	Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 331-40	3.3	9

189	Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 133-43	7	19
188	E-Learning in Urology: Implementation of the Learning and Teaching Platform CASUS - Do Virtual Patients Lead to Improved Learning Outcomes? A Randomized Study among Students. <i>Urologia Internationalis</i> , 2015 , 94, 412-8	1.9	8
187	The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015 , 141, 2061-8	4.9	38
186	Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies. <i>European Urology</i> , 2015 , 68, 713-20	10.2	125
185	Guidelines on Testicular Cancer: 2015 Update. <i>European Urology</i> , 2015 , 68, 1054-68	10.2	398
184	False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 23.e15-23.e21	2.8	15
183	Orderability and the Weinstein conjecture. <i>Compositio Mathematica</i> , 2015 , 151, 2251-2272	1	7
182	Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 144	12.8	20
181	Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09). <i>Oncology</i> , 2015 , 89, 70-8	3.6	18
180	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 76-86	21.7	237
179	Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 185-92	3.3	2
178	Limitations in using 68Ga-PSMA-PET/CT for detection of recurrent disease following radical prostatectomy in patients with prostate cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16110-e16110	2.2	1
177	Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 311-311	2.2	1
176	Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy. <i>Journal of Clinical Oncology</i> , 2015 , 33, 335-335	2.2	
175	Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC). <i>Journal of Clinical Oncology</i> , 2015 , 33, 4527-4527	2.2	
174	Sequential high-dose chemotherapy (HDCT) for relapsed or refractory germ cell cancer (rGCC): Results of a unicentric standardized approach. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15551-e15551	2.2	
173	Histological and perioperative outcomes of post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) in advanced germ cell tumors - A single center experience. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15557-e15557	2.2	
172	Increased signal intensity of prostate lesions on high b-value diffusion-weighted images as a predictive sign of malignancy. <i>European Radiology</i> , 2014 , 24, 209-13	8	16

171	Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 966-74	2.8	28
170	Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer. <i>European Urology</i> , 2014 , 66, 655-63	10.2	13
169	MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy. <i>European Radiology</i> , 2014 , 24, 2582-9	8	72
168	Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate. <i>Journal of Urology</i> , 2014 , 191, 898-906	2.5	38
167	Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 130-7	3.3	26
166	Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen. <i>Journal of Urology</i> , 2014 , 192, 1374-9	2.5	89
165	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 395-8	3.3	11
164	German second-opinion network for testicular cancer: sealing the leaky pipe between evidence and clinical practice. <i>Oncology Reports</i> , 2014 , 31, 2477-81	3.5	20
163	Sequential treatment with taxanes and novel anti-androgenic compounds in castration-resistant prostate cancer. <i>Oncology Research and Treatment</i> , 2014 , 37, 492-8	2.8	9
162	Multiple mechanisms mediate resistance to sorafenib in urothelial cancer. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 20500-17	6.3	18
161	Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05). <i>BJU International</i> , 2014 , 113, 429-36	5.6	57
160	A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. <i>BJU International</i> , 2014 , 113, E137-43	5.6	28
159	Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4500-4500	2.2	6
158	Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 336-336	2.2	1
157	Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 353-353	2.2	1
156	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4514-4514	2.2	
155	Quality of life in patients undergoing paclitaxel-based second-line treatment of urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15508-e15508	2.2	
154	Chemotherapy compared to surgery: Quality-of-life analysis of the German prospective multicenter trial in clinical stage I NSGCT (AUO AH 01/94).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4563-4563	2.2	

153	Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. <i>Investigational New Drugs</i> , 2013 , 31, 1001-7	4.3	21
152	Holmium laser ablation of the prostate (HoLAP): intermediate-term results of 144 patients. <i>World Journal of Urology</i> , 2013 , 31, 1253-9	4	9
151	Translated points and Rabinowitz Floer homology. <i>Journal of Fixed Point Theory and Applications</i> , 2013 , 13, 201-214	1.4	9
150	Exponential decay for sc-gradient flow lines. <i>Journal of Fixed Point Theory and Applications</i> , 2013 , 13, 571-586	1.4	2
149	3-T in-bore MR-guided prostate biopsy based on a scoring system for target lesions characterization. <i>Acta Radiologica</i> , 2013 , 54, 1224-9	2	11
148	Words of wisdom: Re: Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. <i>European Urology</i> , 2013 , 64, 681-2	10.2	1
147	Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 495-500	3.3	16
146	Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?. <i>European Urology</i> , 2013 , 64, 355-7	10.2	26
145	Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1770-9	2.8	55
144	Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. <i>European Urology</i> , 2013 , 63, 717-23	10.2	88
143	Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. <i>European Urology</i> , 2013 , 63, 977-82	10.2	55
142	Active surveillance is the preferred approach to clinical stage I testicular cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3490-3	2.2	103
141	The Conley-Zehnder indices of the rotating Kepler problem. <i>Mathematical Proceedings of the Cambridge Philosophical Society</i> , 2013 , 154, 243-260	0.7	11
140	Randomized phase III study of adjuvant versus progression-triggered treatment with gemcitabine (G) after radical cystectomy (RC) for locally advanced bladder cancer (LABC) in patients not suitable for cisplatin-based chemotherapy (CBC) (AUO-trial AB22/00).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 250-250	2.2	4
139	Options and limitations using 11c-acetate PET/CT imaging for detection of recurrent disease following radical prostatectomy in patients with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e16003-e16003	2.2	
138	Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4524-4524	2.2	
137	Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. <i>European Urology</i> , 2012 , 61, 403-9	10.2	60
136	The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. <i>European Urology</i> , 2012 , 61, 1212-21	10.2	22

135	Contact geometry of the restricted three-body problem. <i>Communications on Pure and Applied Mathematics</i> , 2012 , 65, 229-263	2.5	29
134	Urinary bladder cancer risk in relation to a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor-binding protein-3 (IGFBP3) gene. <i>Archives of Toxicology</i> , 2012 , 86, 195-203	5.8	11
133	A Variational Approach to Givental's Nonlinear Maslov Index. <i>Geometric and Functional Analysis</i> , 2012 , 22, 1033-1050	1.2	6
132	Rs11892031[A] on chromosome 2q37 in an intronic region of the UGT1A locus is associated with urinary bladder cancer risk. <i>Archives of Toxicology</i> , 2012 , 86, 1369-78	5.8	24
131	Management of favorable-risk patients with metastatic renal cell carcinoma: when to start and when to stop targeted therapy. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 213-8	3.3	8
130	Contemporary management of postchemotherapy testis cancer. <i>European Urology</i> , 2012 , 62, 867-76	10.2	76
129	Infinitely many leaf-wise intersections on cotangent bundles 2012 , 30, 168-181		5
128	Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 762-71	2.8	4
127	Comparison of different mathematical models of diffusion-weighted prostate MR imaging. <i>Magnetic Resonance Imaging</i> , 2012 , 30, 1468-74	3.3	46
126	On a theorem by Ekeland-Hofer. <i>Israel Journal of Mathematics</i> , 2012 , 187, 485-491	0.8	2
125	Global Surfaces of Section in the Planar Restricted 3-Body Problem. <i>Archive for Rational Mechanics and Analysis</i> , 2012 , 204, 273-284	2.3	18
124	Design of testis cancer trials: who knows best?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3145-6; author reply 3146-7	2.2	1
123	Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. <i>Journal of Clinical Oncology</i> , 2012 , 30, 792-9	2.2	68
122	Second-line treatment of advanced urothelial cancer with paclitaxel and RAD001 (everolimus) in a German phase II trial (AUO trial AB 35/09).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4590-4590	2.2	1
121	Rabinowitz Floer Homology: A Survey. <i>Springer Proceedings in Mathematics</i> , 2012 , 437-461		13
120	Efficacy of abiraterone acetate in the treatment of castration-resistant prostate cancer: Early results from the German compassionate-use program.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e15195-e15195		2,295
119	Repeat transrectal ultrasound biopsies with additional targeted cores according to results of functional prostate MRI detects high-risk prostate cancer in patients with previous negative biopsy and increased PSA - a pilot study. <i>Anticancer Research</i> , 2012 , 32, 1087-92	2.3	15
118	Testicular germ cell tumors: pathogenesis, diagnosis and treatment. <i>Nature Reviews Endocrinology</i> , 2011 , 7, 43-53	15.2	74

117	830 PATHOHISTOLOGICAL FINDINGS IN PATIENTS WITH NONSEMINOMATOUS GERM CELL TUMOURS (NSGCT) WHO UNDERGO POSTCHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (PC-RPLND) FOR SMALL TUMOURS. <i>Journal of Urology</i> , 2011 , 185,	2.5	10
116	Retrograde balloon dilation >10 weeks after renal transplantation for transplant ureter stenosis - our experience and review of the literature. <i>Arab Journal of Urology Arab Association of Urology</i> , 2011 , 9, 93-9	1.7	6
115	Sunitinib for the treatment of metastatic renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2011 , 37, 178-84.4	37	
114	The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of Oncology. <i>European Journal of Cancer</i> , 2011 , 47, 1-7	7.5	37
113	Diagnosis, staging, and risk factors: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. <i>Urology</i> , 2011 , 78, S427-34	1.6	3
112	Postchemotherapy Retroperitoneal Residual Tumor Resection for Minimal Residual Disease. <i>European Urology Supplements</i> , 2011 , 10, e64-e70	0.9	
111	Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer?. <i>Current Opinion in Urology</i> , 2011 , 21, 434-9	2.8	6
110	Histopathological and molecular features of late relapses in non-seminomas. <i>BJU International</i> , 2011 , 107, 936-43	5.6	19
109	EAU guidelines on testicular cancer: 2011 update. <i>European Urology</i> , 2011 , 60, 304-19	10.2	270
108	Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99). <i>European Urology</i> , 2011 , 60, 1087-96	10.2	21
107	Words of wisdom. Re: Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. Re: Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. <i>European Urology</i> , 2011 , 60, 1124-5	10.2	3
106	Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2191-8	2.2	182
105	Non-displaceable contact embeddings and infinitely many leaf-wise intersections. <i>Journal of Symplectic Geometry</i> , 2011 , 9, 271-284	0.4	5
104	Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 673-8	1.9	38
103	Treatment of Nonseminoma: Stage I 2011 , 147-166		
102	Postchemotherapy Retroperitoneal Lymph Node Dissection 2011 , 225-236		
101	Canadian consensus guidelines for the management of testicular germ cell cancer. <i>Canadian Urological Association Journal</i> , 2010 , 4, e19-38	1.2	99
100	Cup-length estimates for leaf-wise intersections. <i>Mathematical Proceedings of the Cambridge Philosophical Society</i> , 2010 , 149, 539-551	0.7	11

99	Erratum for On the Extrinsic Topology of Lagrangian Submanifolds <i>International Mathematics Research Notices</i> , 2010 , 2010, 1363-1369	0.8	5
98	Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society. <i>Urologia Internationalis</i> , 2010 , 85, 1-10	1.9	29
97	LEAF-WISE INTERSECTIONS AND RABINOWITZ FLOER HOMOLOGY. <i>Journal of Topology and Analysis</i> , 2010 , 02, 77-98	0.3	37
96	Periodic Bounce Orbits of Prescribed Energy. <i>International Mathematics Research Notices</i> , 2010 ,	0.8	2
95	The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010 , 28, 492-9	2.8	35
94	On nonseparating contact hypersurfaces in symplectic 4-manifolds. <i>Algebraic and Geometric Topology</i> , 2010 , 10, 697-737	0.5	11
93	Rs710521[A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk. <i>Archives of Toxicology</i> , 2010 , 84, 967-78	5.8	29
92	Extraperitoneal laparo-endoscopic single-site radical prostatectomy: first experience. <i>World Journal of Urology</i> , 2010 , 28, 705-8	4	20
91	Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity. <i>Histochemistry and Cell Biology</i> , 2010 , 134, 197-204	2.4	25
90	Burden or relief: do second-opinion centers influence the quality of care delivered to patients with testicular germ cell cancer?. <i>European Urology</i> , 2010 , 57, 867-72	10.2	16
89	Organ-sparing surgery for adult testicular tumours: a systematic review of the literature. <i>European Urology</i> , 2010 , 57, 780-90	10.2	134
88	Spectral invariants in Rabinowitz-Floer homology and global Hamiltonian perturbations. <i>Journal of Modern Dynamics</i> , 2010 , 4, 329-357	0.9	17
87	Infertility and testis cancer 2010 , 176-185		
86	On the Weinstein conjecture in higher dimensions. <i>Commentarii Mathematici Helvetici</i> , 2009 , 429-436	0.6	13
85	Germ cell tumors of the gonads: a selective review emphasizing problems in drug resistance and current therapy options. <i>Oncology</i> , 2009 , 76, 77-84	3.6	12
84	Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. <i>European Urology</i> , 2009 , 55, 217-24	10.2	117
83	Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). <i>European Urology</i> , 2009 , 55, 1293-9	10.2	89
82	Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker. <i>BJU International</i> , 2009 , 104, 48-52	5.6	65

81	Retroperitoneal lymph node dissection after chemotherapy. <i>BJU International</i> , 2009 , 104, 1404-12	5.6	26
80	Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. <i>Journal of Urology</i> , 2009 , 181, 363-71	2.5	63
79	CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. <i>Journal of Urology</i> , 2009 , 182, 324-9	2.5	69
78	CPG ISLAND HYPERMETHYLATION IN CELL-FREE, CIRCULATING SERUM DNA PATIENTS WITH TESTICULAR CANCER - A POTENTIAL BIOMARKER. <i>Journal of Urology</i> , 2009 , 181, 200-200	2.5	2
77	Floer homology for negative line bundles and Reeb chords in prequantization spaces. <i>Journal of Modern Dynamics</i> , 2009 , 3, 407-456	0.9	4
76	Maligne Hodentumoren 2009 , 637-738		
75	Words of wisdom. Re: cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. <i>European Urology</i> , 2008 , 53, 208-9	10.2	2
74	European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCCG): part I. <i>European Urology</i> , 2008 , 53, 478-96	10.2	373
73	European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCCG): part II. <i>European Urology</i> , 2008 , 53, 497-513	10.2	194
72	Editorial comment on: laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective. <i>European Urology</i> , 2008 , 54, 1016-7	10.2	2
71	Treatment Approaches in Renal Cell Carcinoma: Past, Present, and Future Perspectives. <i>European Urology Supplements</i> , 2008 , 7, 36-45	0.9	5
70	Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2816-22	2.2	235
69	A nondisplaceable Lagrangian torus in T*S2. <i>Communications on Pure and Applied Mathematics</i> , 2008 , 61, 1046-1051	2.5	9
68	Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. <i>Genes Chromosomes and Cancer</i> , 2008 , 47, 247-52	5	31
67	Seminal vesicle-sparing perineal radical prostatectomy improves early functional results in patients with low-risk prostate cancer. <i>BJU International</i> , 2007 , 100, 1050-4	5.6	12
66	Management of stage I testis cancer. <i>European Urology</i> , 2007 , 51, 34-43; discussion 43-4	10.2	30
65	Radiofrequency ablation of renal tumors improved by preoperative ex-vivo computer simulation model. <i>Journal of Endourology</i> , 2007 , 21, 886-90	2.7	5
64	Clarifying the indications for adjuvant chemotherapy in muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2007 , 4, 184-5		1

63	Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. <i>Journal of Urology</i> , 2007 , 177, 1703-8	2.5	150
62	1001: Retroperitoneal Residual Tumor (RTR) Resection for Testicular Cancer - Template Instead of Full Bilateral Resection. <i>Journal of Urology</i> , 2007 , 177, 331-331	2.5	3
61	Characterisation of the adsorption sites of hydrogen on Pt/C fuel cell catalysts. <i>Catalysis Today</i> , 2006 , 114, 418-421	5.3	31
60	A risk-adapted approach to the treatment of stage I seminoma. <i>Nature Reviews Urology</i> , 2006 , 3, 248-9		
59	Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. <i>Human Molecular Genetics</i> , 2006 , 15, 443-51	5.6	127
58	Organ-Sparing Surgery for Testicular Lesions. <i>European Urology Supplements</i> , 2006 , 5, 522-524	0.9	11
57	Investigation of the glidant properties of compacted colloidal silicon dioxide by angle of repose and X-ray photoelectron spectroscopy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2006 , 63, 356-9	5.7	25
56	Telomerase-pulsed dendritic cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. <i>GMS German Medical Science</i> , 2006 , 4, Doc02	3.2	4
55	A novel component of the ubiquitin pathway, ubiquitin carboxyl extension protein 1 is overexpressed in prostate cancer. <i>International Journal of Molecular Medicine</i> , 2005 , 15, 183	4.4	
54	Cellular retinoic acid-binding protein 2 is down-regulated in prostate cancer 2005 , 27, 1273		1
53	Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. <i>Journal of Urology</i> , 2005 , 173, 824-9	2.5	103
52	Guidelines on testicular cancer. <i>European Urology</i> , 2005 , 48, 885-94	10.2	135
51	Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). <i>Journal of Clinical Oncology</i> , 2005 , 23, 4963-74	2.2	74
50	Modified ureterosigmoidostomy (Mainz Pouch II) in different age groups and with different techniques of ureteric implantation. <i>BJU International</i> , 2004 , 94, 345-9	5.6	21
49	Primary extragonadal germ cell tumor of the prostate in a young man. <i>International Journal of Urology</i> , 2004 , 11, 671-3	2.3	5
48	Health-related quality-of-life following modified ureterosigmoidostomy (Mainz Pouch II) as continent urinary diversion. <i>European Urology</i> , 2004 , 46, 591-7	10.2	17
47	Late relapse of testicular cancer. <i>World Journal of Urology</i> , 2004 , 22, 47-54	4	21
46	Resection of retroperitoneal residual tumor after chemotherapy for testicular cancer indication and surgical techniques. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 50, 79-85	7	7

45	Inelastic neutron scattering studies of hydrogen on fuel cell catalysts. <i>Vibrational Spectroscopy</i> , 2004 , 35, 179-182	2.1	14
44	Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma. <i>Journal of Urology</i> , 2004 , 171, 114-9	2.5	26
43	Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. <i>Journal of Urology</i> , 2004 , 171, 1835-8	2.5	99
42	Phase I/II Trial of Dendritic Cells Pulsed with Telomerase.. <i>Blood</i> , 2004 , 104, 1353-1353	2.2	
41	Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1505-12	2.2	223
40	Surgery in metastatic testicular cancer. <i>European Urology</i> , 2003 , 44, 233-44	10.2	29
39	Angiogenetic protooncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors. <i>European Urology</i> , 2003 , 44, 329-36	10.2	24
38	Corporoplasty for advanced Peyronie's disease using venous and/or dermis patch grafting: new surgical technique and long-term patient satisfaction. <i>Journal of Urology</i> , 2003 , 169, 981-4	2.5	17
37	A new form of noninvasive wound closure with a surgical zipper. <i>Journal of Urology</i> , 2003 , 169, 1785-6	2.5	4
36	Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. <i>Journal of Urology</i> , 2003 , 169, 1710-4	2.5	168
35	Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. <i>Human Gene Therapy</i> , 2003 , 14, 483-94	4.8	135
34	Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4092-9	2.2	136
33	Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2869-75	2.2	138
32	Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. <i>Cancer Immunology, Immunotherapy</i> , 2002 , 51, 637-44	7.4	92
31	Surgery in testis cancer: laparoscopic and open techniques. <i>Current Opinion in Urology</i> , 2002 , 12, 435-40	2.8	9
30	Erythropoietin in urologic oncology. <i>European Urology</i> , 2001 , 39, 1-8	10.2	20
29	Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. <i>Human Gene Therapy</i> , 2001 , 12, 267-78	4.8	73
28	Organ sparing surgery for malignant germ cell tumor of the testis. <i>Journal of Urology</i> , 2001 , 166, 2161-5	2.5	243

27	Viabie malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2647-57	2.2	212
26	Inelastic Neutron Scattering Investigation of the Nature of Surface Sites Occupied by Hydrogen on Highly Dispersed Platinum on Commercial Carbon Black Supports. <i>Journal of Catalysis</i> , 2000 , 196, 174-179	7.3	23
25	Eukaryotic initiation factor 3 p110 mRNA is overexpressed in testicular seminomas. <i>American Journal of Pathology</i> , 2000 , 157, 1597-604	5.8	51
24	SALVAGE SURGERY OF CHEMOREFRACTORY GERM CELL TUMORS WITH ELEVATED TUMOR MARKERS. <i>Journal of Urology</i> , 2000 , 164, 381-384	2.5	90
23	Loss of heterozygosity, differentiation, and clonality in microdissected male germ cell tumours. <i>Journal of Pathology</i> , 1999 , 188, 389-94	9.4	27
22	Risk factors for relapse in stage I non-seminomatous germ-cell tumors: preliminary results of the German Multicenter Trial. German Testicular Cancer Study Group. <i>International Journal of Cancer</i> , 1999 , 83, 828-30	7.5	13
21	Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. <i>Urology</i> , 1999 , 53, 808-11	1.6	130
20	Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumors. <i>Urology</i> , 1999 , 54, 714-8	1.6	25
19	SIMS/XPS Study on the Deactivation and Reactivation of B-MFI Catalysts Used in the Vapour-Phase Beckmann Rearrangement. <i>Journal of Catalysis</i> , 1998 , 176, 561-568	7.3	43
18	Registerstudie für die Behandlung von Hirnmetastasen maligner Hodentumoren. <i>Strahlentherapie Und Onkologie</i> , 1998 , 174, 339-339	4.3	
17	Fluorescence in situ hybridization on nuclei from paraffin-embedded tissue in low stage pure embryonal carcinoma of the testis. <i>Journal of Urology</i> , 1998 , 159, 240-4	2.5	18
16	Efficient photo-assisted Fenton catalysis mediated by Fe ions on Nafion membranes active in the abatement of non-biodegradable azo-dye. <i>Chemical Communications</i> , 1998 , 1493-1494	5.8	74
15	Management of complete ureteral replacement. Experiences and review of the literature. <i>Scandinavian Journal of Urology and Nephrology</i> , 1997 , 31, 383-8		22
14	MIB-1 immunohistochemistry in clinical Stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis 1997 , 79, 1710-1716		38
13	Long-Term Results of Internal Urethrotomy. <i>Journal of Urology</i> , 1996 , 156, 1611-1614	2.5	121
12	Tumor Proliferative Activity is Predictive of Pathological Stage in Clinical Stage a Nonseminomatous Testicular Germ Cell Tumors. <i>Journal of Urology</i> , 1996 , 155, 579-586	2.5	38
11	Tumor Proliferative Activity is Predictive of Pathological Stage in Clinical Stage a Nonseminomatous Testicular Germ Cell Tumors. <i>Journal of Urology</i> , 1996 , 579-586	2.5	1
10	Ectopic ureters and ureteroceles in adults. <i>Urology</i> , 1995 , 45, 870-4	1.6	19

9	Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage A nonseminomatous testicular germ cell tumor at low risk for occult metastasis. <i>Cancer</i> , 1995 , 75, 844-50	6.4	25
8	Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors. <i>Cancer</i> , 1994 , 74, 1335-41	6.4	27
7	Flow-cytometric and quantitative histologic parameters as prognostic indicators for occult retroperitoneal disease in clinical-stage-I non-seminomatous testicular germ-cell tumors. <i>International Journal of Cancer</i> , 1994 , 57, 628-33	7.5	29
6	Oxidative coupling of methane. The effect of alkali chlorides on molybdate based catalyst leading to high selectivity in C3-product formation. <i>Catalysis Letters</i> , 1993 , 18, 15-26	2.8	4
5	Oxidative coupling of methane over molybdates: catalyst performance and characterization. <i>The Journal of Physical Chemistry</i> , 1992 , 96, 1344-1349		10
4	Testicular germ cell tumours368-383		
3	Testicular Germ Cell Tumours368-383		
2	Pseudorotations of the S^1 -sphere. <i>Ergodic Theory and Dynamical Systems</i> ,1-35	0.9	1
1	A Symplectic Dynamics Proof of the Degree-Poincaré Formula. <i>Arnold Mathematical Journal</i> ,1	0.3	0